Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.

MLA

Chen, Sha, et al. “Empagliflozin Prevents Heart Failure through Inhibition of the NHE1-NO Pathway, Independent of SGLT2.” Basic Research in Cardiology, vol. 119, no. 5, Oct. 2024, pp. 751–72. EBSCOhost, https://doi.org/10.1007/s00395-024-01067-9.

APA

Chen, S., Wang, Q., Bakker, D., Hu, X., Zhang, L., van der Made, I., Tebbens, A. M., Kovácsházi, C., Giricz, Z., Brenner, G. B., Ferdinandy, P., Schaart, G., Gemmink, A., Hesselink, M. K. C., Rivaud, M. R., Pieper, M. P., Hollmann, M. W., Weber, N. C., Balligand, J.-L., … Zuurbier, C. J. (2024). Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Research in Cardiology, 119(5), 751–772. https://doi.org/10.1007/s00395-024-01067-9

Chicago

Chen, Sha, Qian Wang, Diane Bakker, Xin Hu, Liping Zhang, Ingeborg van der Made, Anna M Tebbens, et al. 2024. “Empagliflozin Prevents Heart Failure through Inhibition of the NHE1-NO Pathway, Independent of SGLT2.” Basic Research in Cardiology 119 (5): 751–72. doi:10.1007/s00395-024-01067-9.